Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jiajia Li, Yihua Sun, Xiuling Zhi, Yating Sun, Zulimire Abudousalamu, Qianhan Lin, Bin Li, Liangqing Yao, Mo Chen
BACKGROUND: Lymph node metastasis (LNM) is a major factor contributing to the high mortality rate of ovarian cancer, making the treatment of this disease challenging. However, the molecular mechanism underlying LNM in ovarian cancer is still not well understood, posing a significant obstacle to overcome. RESULTS: Through data mining from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we have identified MEOX1 as a specific gene associated with LNM in ovarian cancer...
March 14, 2024: Journal of Ovarian Research
#22
JOURNAL ARTICLE
Nicholas W Bateman, Tamara Abulez, Anthony R Soltis, Andrew McPherson, Seongmin Choi, Dale W Garsed, Ahwan Pandey, Chunqiao Tian, Brian L Hood, Kelly A Conrads, Pang-Ning Teng, Julie Oliver, Glenn Gist, Dave Mitchell, Tracy J Litzi, Christopher M Tarney, Barbara A Crothers, Paulette Mhawech-Fauceglia, Clifton L Dalgard, Matthew D Wilkerson, Mariaelena Pierobon, Emanuel F Petricoin, Chunhua Yan, Daoud Meerzaman, Clara Bodelon, Nicolas Wentzensen, Jerry S H Lee, David G Huntsman, Sohrab Shah, Craig D Shriver, Neil T Phippen, Kathleen M Darcy, David D L Bowtell, Thomas P Conrads, G Larry Maxwell
We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity. We identified patients with longer progression-free survival had increased immune-related signatures and validated proteins correlating with tumor-infiltrating lymphocytes in 65 tumors from an independent cohort of HGSOC patients, as well as with overall survival in an additional 126 HGSOC patient cohort...
March 13, 2024: NPJ Precision Oncology
#23
JOURNAL ARTICLE
Dianning He, Xin Zhang, Zhihui Chang, Zhaoyu Liu, Beibei Li
BACKGROUND: The presence of heterogeneity is a significant attribute within the context of ovarian cancer. This study aimed to assess the predictive accuracy of models utilizing quantitative 18 F-FDG PET/CT derived inter-tumor heterogeneity metrics in determining progression-free survival (PFS) and overall survival (OS) in patients diagnosed with high-grade serous ovarian cancer (HGSOC). Additionally, the study investigated the potential correlation between model risk scores and the expression levels of p53 and Ki-67...
March 12, 2024: BMC Cancer
#24
REVIEW
Christine Pampeno, Silvana Opp, Alicia Hurtado, Daniel Meruelo
This review article provides a comprehensive overview of a novel Sindbis virus vaccine platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most lethal of all gynecological malignancies. The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed with advanced disease. Current treatment options are very aggressive and limited, resulting in tumor recurrences and 50-60% patient mortality within 5 years. The unique properties of armed oncolytic Sindbis virus vectors (SV) in vivo have garnered significant interest in recent years to potently target and treat ovarian cancer...
March 2, 2024: International Journal of Molecular Sciences
#25
JOURNAL ARTICLE
Jiajia Li, Dongzhen Liu, Man Cui, Zhentong Wei
High-grade serous ovarian cancer (HGSOC) has a high death rate and poor prognosis. The main causes of poor prognosis are asymptomatic early disease, no effective screening method at present, and advanced disease. Changes in cellular metabolism are characteristic of cancer, and plasma metabolome analysis can be used to identify biomarkers. In this study, we used Q Exactive liquid chromatography tandem mass spectrometry (LC-MS/MS, QE) to compare the differentiation between plasma samples (22 HGSOC samples and 22 normal samples)...
March 10, 2024: Journal of Proteomics
#26
JOURNAL ARTICLE
Heng-Cheng Hsu, Hung-Hsueh Chou, Wen-Fang Cheng, Chih-Long Chang
BACKGROUND: This study was designed to investigate the demographics, treatment patterns, and clinical outcomes of patients newly diagnosed with high-grade serous ovarian cancer (HGSOC) in 3 medical centers in Taiwan before the integration of poly (ADP-ribose) polymerase inhibitors in clinical practice. METHODS: A retrospective analysis was conducted on data from patients diagnosed with HGSOC between January 2014 and December 2018 and followed-up for a minimum of 12 months after diagnosis...
March 6, 2024: Journal of the Formosan Medical Association
#27
JOURNAL ARTICLE
Dhanya Ramachandran, Jonathan P Tyrer, Stefan Kommoss, Anna DeFazio, Marjorie J Riggan, Penelope M Webb, Peter A Fasching, Diether Lambrechts, María J García, Cristina Rodríguez-Antona, Marc T Goodman, Francesmary Modugno, Kirsten B Moysich, Beth Y Karlan, Jenny Lester, Susanne K Kjaer, Allan Jensen, Estrid Høgdall, Ellen L Goode, William A Cliby, Amanika Kumar, Chen Wang, Julie M Cunningham, Stacey J Winham, Alvaro N Monteiro, Joellen M Schildkraut, Daniel W Cramer, Kathryn L Terry, Linda Titus, Line Bjorge, Liv Cecilie Vestrheim Thomsen, Tanja Pejovic, Claus K Høgdall, Iain A McNeish, Taymaa May, David G Huntsman, Jacobus Pfisterer, Ulrich Canzler, Tjoung-Won Park-Simon, Willibald Schröder, Antje Belau, Lars Hanker, Philipp Harter, Jalid Sehouli, Rainer Kimmig, Nikolaus de Gregorio, Barbara Schmalfeldt, Klaus Baumann, Felix Hilpert, Alexander Burges, Boris Winterhoff, Peter Schürmann, Lisa-Marie Speith, Peter Hillemanns, Andrew Berchuck, Sharon E Johnatty, Susan J Ramus, Georgia Chenevix-Trench, Paul D P Pharoah, Thilo Dörk, Florian Heitz
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous carcinoma (HGSOC), to identify variants associated with residual disease. The most significant association with resection status was observed for rs72845444, upstream of MGMT, in HGSOC (p = 3.9 × 10-8 ). In gene-based analyses, PPP2R5C was the most strongly associated gene in HGSOC after stage adjustment...
March 5, 2024: NPJ Genomic Medicine
#28
JOURNAL ARTICLE
Pang-Ning Teng, Joshua P Schaaf, Tamara Abulez, Brian L Hood, Katlin N Wilson, Tracy J Litzi, David Mitchell, Kelly A Conrads, Allison L Hunt, Victoria Olowu, Julie Oliver, Fred S Park, Marshé Edwards, AiChun Chiang, Matthew D Wilkerson, Praveen-Kumar Raj-Kumar, Christopher M Tarney, Kathleen M Darcy, Neil T Phippen, G Larry Maxwell, Thomas P Conrads, Nicholas W Bateman
Numerous multi-omic investigations of cancer tissue have documented varying and poor pairwise transcript:protein quantitative correlations, and most deconvolution tools aiming to predict cell type proportions (cell admixture) have been developed and credentialed using transcript-level data alone. To estimate cell admixture using protein abundance data, we analyzed proteome and transcriptome data generated from contrived admixtures of tumor, stroma, and immune cell models or those selectively harvested from the tissue microenvironment by laser microdissection from high grade serous ovarian cancer (HGSOC) tumors...
March 15, 2024: IScience
#29
JOURNAL ARTICLE
Adi Alfandari, Dotan Moskovich, Avivit Weisz, Aviva Katzav, Debora Kidron, Mario Beiner, Dana Josephy, Aula Asali, Yael Hants, Yael Yagur, Omer Weitzner, Martin Ellis, Gilad Itchaki, Osnat Ashur-Fabian
The selenoenzyme type I iodothyronine deiodinase (DIO1) catalyzes removal of iodine atoms from thyroid hormones. Although DIO1 action is reported to be disturbed in several malignancies, no work has been conducted in high-grade serous ovarian carcinoma (HGSOC), the most lethal gynecologic cancer. We studied DIO1 expression in HGSOC patients [The Cancer Genome Atlas (TCGA) data and tumor tissues], human cell lines (ES-2 and Kuramochi), normal Chinese hamster ovarian cells (CHO-K1), and normal human fallopian tube cells (FT282 and FT109)...
March 1, 2024: Molecular Oncology
#30
JOURNAL ARTICLE
Emilie Wong Chong, France-Hélène Joncas, Pierre Douville, Dimcho Bachvarov, Caroline Diorio, Frédéric Calon, Ann-Charlotte Bergeron, Jonatan Blais, Shuk On Annie Leung, Nabil Georges Seidah, Anne Gangloff
Cancer cells need constant supplies of lipids to survive and grow. Lipid dependence has been observed in various types of cancer, including high-grade serous ovarian carcinomas (HGSOC), which is a lethal form of gynecological malignancy. ANGPTL3, PCSK9, and Apo CIII are pivotal lipid-modulating factors, and therapeutic antibodies have been developed against each one (Evinacumab, Evolocumab and Volanesorsen, respectively). The roles -if any- of ANGPTL3, PCSK9, and Apo CIII in HGSOC are unclear. Moreover, levels of these lipid-modulating factors have never been reported before in HGSOC...
February 27, 2024: Lipids in Health and Disease
#31
JOURNAL ARTICLE
Rafał Watrowski, Eva Schuster, Gerda Hofstetter, Michael B Fischer, Sven Mahner, Toon Van Gorp, Stefan Polterauer, Robert Zeillinger, Eva Obermayr
Interleukin-8 (IL-8) is involved in the regulation of inflammatory processes and carcinogenesis. Single-nucleotide polymorphisms (SNPs) within the IL-8 gene have been shown to alter the risks of lung, gastric, or hepatocellular carcinomas. To date, only one study examined the role of IL-8 SNPs in ovarian cancer (OC), suggesting an association between two IL-8 SNPs and OC risk. In this study, we investigated four common IL-8 SNPs, rs4073 (-251 A>T), rs2227306 (+781 C>T), rs2227543 (+1633 C>T), and rs1126647 (+2767 A>T), using the restriction fragment length polymorphism (PCR-RFLP) technique...
January 30, 2024: Biomedicines
#32
REVIEW
Ricardo Roque, Ilda Patrícia Ribeiro, Margarida Figueiredo-Dias, Charlie Gourley, Isabel Marques Carreira
Circulating tumour DNA (ctDNA) facilitates longitudinal study of the tumour genome, which, unlike tumour tissue biopsies, globally reflects intratumor and intermetastatis heterogeneity. Despite its costs, next-generation sequencing (NGS) has revolutionised the study of ctDNA, ensuring a more comprehensive and multimodal approach, increasing data collection, and introducing new variables that can be correlated with clinical outcomes. Current NGS strategies can comprise a tumour-informed set of genes or the entire genome and detect a tumour fraction as low as 10-5 ...
January 31, 2024: Biology
#33
JOURNAL ARTICLE
Yue Qi, Jinchi Liu, Xinyue Wang, Yuqing Zhang, Zhixun Li, Xinyu Qi, Ying Huang
BACKGROUND: Despite advances in medical imaging technology, the accurate preoperative prediction of lymph node status remains challenging in ovarian cancer. This retrospective study aimed to investigate the feasibility of using ultrasound-based radiomics combined with preoperative clinical characteristics to predict lymph node metastasis (LNM) in patients with high-grade serous ovarian cancer (HGSOC). RESULTS: Patients with 401 HGSOC lesions from two institutions were enrolled: institution 1 for the training cohort (n = 322) and institution 2 for the external test cohort (n = 79)...
February 22, 2024: Journal of Ovarian Research
#34
JOURNAL ARTICLE
Cong Ye, Yan Cheng, Xiaohong Qian, Bo Zhong, Jinchun Ma, Hongling Guo
Cell senescence is an anti-cancer strategy following DNA repair and apoptosis, which is associated with the initiation, progression, and treatment of ovarian cancer. The CDK4/6 inhibitor alters cell cycle and induces cell senescence dependent on retinoblastoma (RB) family proteins. Objective Herein, we aimed to explore the effects of Palbociclib (a CDK4/6 inhibitor) on cellular senescence of high-grade serous ovarian cancer (HGSOC). Cell viability and cell cycle were evaluated by cell counting kit-8 and flow cytometry...
February 22, 2024: Biochemical Genetics
#35
JOURNAL ARTICLE
Le Fu, Wenjing Wang, Lingling Lin, Feng Gao, Jiani Yang, Yunyun Lv, Ruiqiu Ge, Meixuan Wu, Lei Chen, Aie Liu, Enhui Xin, Jianli Yu, Jiejun Cheng, Yu Wang
OBJECTIVE: High-grade serous ovarian cancer (HGSOC) has the highest mortality rate among female reproductive system tumors. Accurate preoperative assessment is crucial for treatment planning. This study aims to develop multitask prediction models for HGSOC using radiomics analysis based on preoperative CT images. METHODS: This study enrolled 112 patients diagnosed with HGSOC. Laboratory findings, including serum levels of CA125, HE-4, and NLR, were collected. Radiomic features were extracted from manually delineated ROI on CT images by two radiologists...
2024: Frontiers in Medicine
#36
JOURNAL ARTICLE
Anna Perkiö, Barun Pradhan, Fatih Genc, Anna Pirttikoski, Sanna Pikkusaari, Erdogan Pekcan Erkan, Matias Marin Falco, Kaisa Huhtinen, Sara Narva, Johanna Hynninen, Liisa Kauppi, Anna Vähärautio
Long interspersed nuclear elements (LINE-1s/L1s) are a group of retrotransposons that can copy themselves within a genome. In humans, it is the most successful transposon in nucleotide content. L1 expression is generally mild in normal human tissues, but the activity has been shown to increase significantly in many cancers. Few studies have examined L1 expression at single-cell resolution, thus it is undetermined whether L1 reactivation occurs solely in malignant cells within tumors. One of the cancer types with frequent L1 activity is high-grade serous ovarian carcinoma (HGSOC)...
February 21, 2024: Scientific Reports
#37
JOURNAL ARTICLE
Carly B Scalise, Kaitlyn Kincaid, Haley Thigpen, Jennah Moore, Bailee Dover, Lyse Norian, Selene Meza-Perez, Troy Randall, Michael Birrer, Kunle Odunsi, Rebecca C Arend
OBJECTIVE: Advanced-stage high-grade serous ovarian cancer (HGSOC) remains a deadly gynecologic malignancy with high rates of disease recurrence and limited, effective therapeutic options for patients. There is a significant need to better stratify HGSOC patients into platinum refractory (PRF) vs. sensitive (PS) cohorts at baseline to improve therapeutic responses and survival outcomes for PRF HGSOC. METHODS: We performed NanoString for GeoMx Digital Spatial Profile (G-DSP) multiplex protein analysis on PRF and PS tissue microarrays (TMAs) to study the bidirectional communication of cancer cells with immune cells in the tumor microenvironment (TME) of HGSOC...
February 19, 2024: Gynecologic Oncology
#38
JOURNAL ARTICLE
Cyrus Takahashi, Mikhail Chtcherbinine, Brandt C Huddle, Michael W Wilson, Timothy Emmel, Robert M Hohlman, Stacy McGonigal, Ronald J Buckanovich, Scott D Larsen, Thomas D Hurley
Aldehyde dehydrogenase 1A (ALDH1A) isoforms may be a useful target for overcoming chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) and other solid tumor cancers. However, as different cancers express different ALDH1A isoforms, isoform selective inhibitors may have a limited therapeutic scope. Furthermore, resistance to an ALDH1A isoform selective inhibitor could arise via induction of expression of other ALDH1A isoforms. As such, we have focused on the development of pan-ALDH1A inhibitors, rather than on ALDH1A isoform selective compounds...
February 14, 2024: Chemico-biological Interactions
#39
JOURNAL ARTICLE
Nanna Monjé, Mihnea P Dragomir, Bruno V Sinn, Inga Hoffmann, Anuar Makhmut, Tincy Simon, Catarina A Kunze, Jana Ihlow, Wolfgang D Schmitt, Jonathan Pohl, Iris Piwonski, Sofya Marchenko, Carlotta Keunecke, Teodor G Calina, Francesca Tiso, Hagen Kulbe, Caroline Kreuzinger, Dan Cacsire Castillo-Tong, Jalid Sehouli, Elena I Braicu, Carsten Denkert, Silvia Darb-Esfahani, Kirsten Kübler, David Capper, Fabian Coscia, Markus Morkel, David Horst, Christine Sers, Eliane T Taube
BACKGROUND: The aim of this study was to analyse transcriptomic differences between primary and recurrent high-grade serous ovarian carcinoma (HGSOC) to identify prognostic biomarkers. METHODS: We analysed 19 paired primary and recurrent HGSOC samples using targeted RNA sequencing. We selected the best candidates using in silico survival and pathway analysis and validated the biomarkers using immunohistochemistry on a cohort of 44 paired samples, an additional cohort of 504 primary HGSOCs and explored their function...
February 9, 2024: British Journal of Cancer
#40
JOURNAL ARTICLE
M R Farook, Z Croxford, S Morgan, A D Horlock, A Holt, A Rees, B J Jenkins, C Tse, E Stanton, D M Davies, C A Thornton, N Jones, I M Sheldon, E E Vincent, J G Cronin
The pyruvate transporter MPC1 (mitochondrial pyruvate carrier 1) acts as a tumour-suppressor, loss of which correlates with a pro-tumorigenic phenotype and poor survival in several tumour types. In high-grade serous ovarian cancers (HGSOC), patients display copy number loss of MPC1 in around 78% of cases and reduced MPC1 mRNA expression. To explore the metabolic effect of reduced expression, we demonstrate that depleting MPC1 in HGSOC cell lines drives expression of key proline biosynthetic genes; PYCR1, PYCR2 and PYCR3, and biosynthesis of proline...
February 12, 2024: Molecular Metabolism
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
